Immunomedics, Inc. (NASDAQ:IMMU) registered a -4.52% decrease, still its new closing price is 175.78% up from the company’s 1 year high of 5.44.It posted 1.37% gains in previous 5 sessions and is now the subject of 1 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 1 buy or better ratings. The 2 stock analysts following this company have an average price target at $6.00, with individual PT in the $6.00-$6.00 range. The shares moved at $4.44, implying that brokerage firms see shares gaining about 136.17% in twelve months time.

Immunomedics, Inc. (IMMU) SEC Form 4 News

The stock is getting much attention these days as insiders are offloading shares while they posted a 20.98% rise year to date. A Director at Immunomedics, Inc. (IMMU) offloaded shares in a transaction closed on Wednesday August 24, 2016. Stark Don C sold 9,900 shares in the company at $2.97 each and collected $29,000 in proceeds. Stark Don C now owns 55,848 shares in the company after this transaction. A Director in the company, MARKISON BRIAN A, disclosed a transaction on Tuesday August 23, 2016 that ended up generating $44,001 from the sale of 15,000 shares at $2.98 per share.

Immunomedics, Inc. (NASDAQ:IMMU) Upcoming Results on Tap

Immunomedics, Inc. will next provide financial results for the September 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.07 in that period. Sales during the quarter are predicted to arrive at $12.7 million.

Earnings surprise history: Last quarter, the company posted approximately $1 in revenue and EPS of $-0.17. The mean forecast was for $3.1 million and $-0.14 a share, respectively. One quarter earlier, revenue for the stock was at $1, with earnings at $-0.17/share.

Immunomedics, Inc. (IMMU) Brokerage Update

Immunomedics, Inc. (IMMU) is in Wells Fargo’s research list so their analyst rating change is noteworthy. These shares were downgraded to Market Perform from Outperform by Wells Fargo, according to news reported on Tuesday June 21, 2016.Another important research note was issued by Jefferies on Friday May 06, 2016.The firm upgraded IMMU to Buy from Hold. Over the last six months and over the last three months, the shares of Immunomedics, Inc. (IMMU), have changed 67.55% and 102.74%, respectively.